A Prudential Stock Investment Move? ROC Plans to Go Public.

If Spotify has assigned you a high estimated age, you may recall Prudential’s “get a piece of the rock” advertising campaign from the last century.

From https://youtu.be/LaaisYNYxvs?si=_6-JsFsRq1O9ar7y.

Well, people in the 21st century can now “get a piece of the ROC,” or own shares in the company initially known as Rank One Computing.

Biometric Update alerted us to ROC’s filing with the Securities and Exchange Commission. Technically this is a “preliminary prospectus” awaiting SEC approval and final pricing, but it gives you an idea of what ROC is, what they’ve done, and what they’d like to do.

“ROC is an independent American artificial intelligence company redefining the global standard for Vision AI in identity, security, and digital forensics. Our Vision AI platform delivers real-time facial recognition, multimodal biometric verification, video analytics, and AI-powered evidence analysis to mission-critical organizations across both private and public sectors. ROC’s biometric algorithms are routinely ranked by National Institute of Standards and Technology (“NIST”) as among the most accurate and computationally efficient globally. Our solutions outperform legacy foreign-built systems at a fraction of the cost, with faster deployment and stronger trust. As demand for trusted AI accelerates across law enforcement, defense, and regulated commercial sectors, ROC is scaling rapidly through a growing network of integrators and multi-year deals. We are expanding from a foundation of government leadership into high-growth commercial markets such as access control, physical security, and identity verification. Our international pipeline spans the Middle East, Asia–Pacific (“APAC”), and other strategic regions where national AI and identity investments are surging. With sovereign U.S. development, deep technical leadership, a vertically integrated platform, and proven field results, we believe ROC is positioned to become the category-defining leader in operational Vision AI.”

Of course, as ROC enters new markets, its “made in the USA” strength could potentially become a weakness. For example, EU regulators may (or may not) become wary of using algorithms from a non-EU company. And forget about Russia.

Any SEC-governed statement must detail risks to ensure that investors are not misled, and ROC lists the types of risks that one might expect (dependence upon certain types of customers, complex product lines, etc.). But this particular risk caught my eye:

“If we are unable to successfully deploy our marketing and sales organization in a timely manner, or at all, or to successfully hire, retain, train, and motivate our sales personnel, our growth could be adversely impacted.”

Hey Scott…

Also buried in the preliminary prospectus are sales and cost figures from 2023, 2024, and the first 9 months of 2025; a note that two customers accounted for 45% of ROC’s revenue in the first nine months of 2025; the negative consequences of ROC’s mission “to support Western liberal democracy and its strategic allies” (companies with fewer scruples can sell to all sorts of entities that ROC won’t touch); risks related to artificial intelligence (not an issue when Printrak went public in the 1990s); and many, many, many other risks.

Because that’s what you say when you want to go public. You always, always use caution when talking to investors.

So we’ll see what happens. Is this a good time for an IPO?

I’m Bot a Doctor, Google MedGemma and MedSigLIP Edition

The Instagram account acknowledge.aI posted the following (in part):

“Google has released its MedGemma and MedSigLIP models to the public, and they’re powerful enough to analyse chest X-rays, medical images, and patient histories like a digital second opinion.”

Um, didn’t we just address this on Wednesday?

“In the United States, it is a criminal offense for a person to claim they are a health professional when they are not. But what about a non-person entity?”

Google and developers

So I wanted to see how Google offered MedGemma and MedSigLIP. So I found Google’s own July 9 announcement

In the announcement, Google asserted that their tools are privacy-preserving, allowing developers to control privacy. In fact, developers are frequently mentioned in the announcement. Yes, developers.

OH wait, that was Microsoft.

The implication: Google just provides the tool: developers are responsible for its use. And the long disclaimer includes this sentence:

“The outputs generated by these models are not intended to directly inform clinical diagnosis, patient management decisions, treatment recommendations, or any other direct clinical practice applications.”

We’ve faced this before

And we’ve addressed this also, regarding proper use of facial recognition ONLY as an investigative lead. Responsible vendors emphasize this:

“In a piece on the ethical use of facial recognition, Rank One Computing stated the following in passing:

“‘[Rank One Computing] is taking a proactive stand to communicate that public concerns should focus on applications and policies rather than the technology itself.’”

But just because ROC or Clearview AI or another vendor communicates that facial recognition should ONLY be used as an investigative lead…does that mean that their customers will listen?

connect:ID 2021 is coming

I have not been to an identity trade show in years, and sadly I won’t be in Washington DC next week for connect:ID…although I’ll be thinking about it.

I’ve only been to connect:ID once, in 2015. Back in those days I was a strategic marketer with MorphoTrak, and we were demonstrating the MorphoWay. No, not the Morpho Way; the MorphoWay.

At connect:ID 2015.

Perhaps you’ve seen the video.

Video by Biometric Update. https://www.youtube.com/watch?v=mqfHAc227As

As an aside, you’ll notice how big MorphoWay is…which renders it impractical for use in U.S. airports, since space is valuable and therefore security features need a minimum footprint. MorphoWay has a maximum footprint…just ask the tradespeople who were responsible for getting it on and off the trade show floor.

I still remember several other things from this conference. For example, in those days one of Safran’s biometric competitors was 3M. Of course both Safran and 3M have exited the biometric industry, but at the time they were competing against each other. Companies always make a point of checking out the other companies at these conferences, but when I went to 3M’s booth, the one person I knew best (Teresa Wu) was not at the booth. Later that year, Teresa would leave 3M and (re)join Safran, where she remains to this day.

Yes, there is a lot of movement of people between firms. Looking over the companies in the connect:ID 2021 Exhibitor Directory, I know people at a number of these firms. Obviously people from IDEMIA, of course (IDEMIA was the company that bought Safran’s identity business), but I also know people at other companies, all of whom who were former coworkers at IDEMIA or one of its predecessor companies:

  • Aware.
  • Clearview AI.
  • GET Group North America.
  • HID Global.
  • Integrated Biometrics.
  • iProov.
  • NEC.
  • Paravision.
  • Rank One Computing.
  • SAFR/RealNetworks.
  • Thales.
  • Probably some others that I missed.

And I know people at some of the other companies, organizations, and governmental entities that are at connect:ID this year.

Some of these entities didn’t even exist when I was at connect:ID six years ago, and some of these entities (such as Thales) have entered the identity market due to acquisitions (in Thales’ case, the acquisition of Gemalto, which had acquired 3M’s biometric business).

So while I’m not crossing the country next week, I’m obviously thinking of everything that will be going on there.

Incidentally, this is one of the last events of the trade show season, which is starting to wind down for the year. But it will ramp up again next spring (for you Northern Hemisphere folks).

Bredemarket remembers the Southern Hemisphere, even though Bredemarket only does business in the United States. https://www.youtube.com/watch?v=HtZCQiN3n50

Regardless of where you are, hopefully the upcoming trade show season will not be adversely impacted by the pandemic.